Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Protease inhibitor-associated QT interval prolongation.

Hunt K, Hughes CA, Hills-Nieminen C.

Ann Pharmacother. 2011 Dec;45(12):1544-50. doi: 10.1345/aph.1Q422. Epub 2011 Nov 29. Review.

PMID:
22128044
2.

Azithromycin-induced proarrhythmia and cardiovascular death.

Howard PA.

Ann Pharmacother. 2013 Nov;47(11):1547-51. doi: 10.1177/1060028013504905. Review.

PMID:
24285766
3.

Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?

Mayet S, Gossop M, Lintzeris N, Markides V, Strang J.

Drug Alcohol Rev. 2011 Jul;30(4):388-96. doi: 10.1111/j.1465-3362.2010.00237.x. Epub 2010 Sep 6.

PMID:
21355918
4.

Warfarin-antiretroviral interactions.

Liedtke MD, Rathbun RC.

Ann Pharmacother. 2009 Feb;43(2):322-8. doi: 10.1345/aph.1L497. Epub 2009 Feb 5. Review.

PMID:
19196837
5.

Prolonged QT interval and torsades de pointes associated with atazanavir therapy.

Ly T, Ruiz ME.

Clin Infect Dis. 2007 Mar 15;44(6):e67-8. Epub 2007 Feb 1.

PMID:
17304444
6.

QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.

Briasoulis A, Agarwal V, Pierce WJ.

Cardiology. 2011;120(2):103-10. doi: 10.1159/000334441. Epub 2011 Dec 13. Review.

PMID:
22156660
7.

QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.

Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F.

Am J Cardiol. 2003 Oct 15;92(8):995-7.

PMID:
14556883
8.

Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.

Halkin A, Roth A, Lurie I, Fish R, Belhassen B, Viskin S.

J Am Coll Cardiol. 2001 Oct;38(4):1168-74.

9.

Long QTc and torsades de pointes in human immunodeficiency virus disease.

Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ.

Pacing Clin Electrophysiol. 1997 Nov;20(11):2810-6.

PMID:
9392812
10.

Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study.

Charbit B, Rosier A, Bollens D, Boccara F, Boelle PY, Koubaa A, Girard PM, Funck-Brentano C.

Br J Clin Pharmacol. 2009 Jan;67(1):76-82. doi: 10.1111/j.1365-2125.2008.03332.x. Epub 2008 Nov 17.

11.

Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?

Samuelov-Kinori L, Kinori M, Kogan Y, Swartzon M, Shalev H, Guy D, Ferenidou F, Mashav N, Sadeh B, Atzmony L, Kliuk-Ben-Basat O, Steinvil A, Justo D.

J Electrocardiol. 2009 Jul-Aug;42(4):353-357.e1. doi: 10.1016/j.jelectrocard.2009.01.005. Epub 2009 Mar 3.

PMID:
19261294
12.

High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.

Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, Liu JN, Drew BJ.

Crit Care Med. 2012 Feb;40(2):394-9. doi: 10.1097/CCM.0b013e318232db4a.

PMID:
22001585
13.

QT interval prolongation, torsade de pointes and renal disease.

Patanè S, Marte F, Di Bella G, Currò A, Coglitore S.

Int J Cardiol. 2008 Nov 12;130(2):e71-3. doi: 10.1016/j.ijcard.2007.11.070. Epub 2008 Feb 5.

PMID:
18255176
14.

Proarrhythmic potential of antimicrobial agents.

Simkó J, Csilek A, Karászi J, Lorincz I.

Infection. 2008 Jun;36(3):194-206. doi: 10.1007/s15010-007-7211-8. Epub 2008 May 3. Review.

PMID:
18454341
15.

Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS.

Pharmacotherapy. 2003 Jun;23(6):802-5.

PMID:
12820821
16.

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.

J Cardiovasc Pharmacol. 2001 May;37(5):607-18.

PMID:
11336111
17.

Antimicrobial agents-associated with QT interval prolongation.

Bril F, Gonzalez CD, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):85-92. Review.

PMID:
20210724
18.

Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.

Patel N, Veve M, Kwon S, McNutt LA, Fish D, Miller CD.

HIV Med. 2013 Sep;14(8):463-71. doi: 10.1111/hiv.12031. Epub 2013 Mar 18.

19.

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.

Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.

Circulation. 1992 Nov;86(5):1376-82.

PMID:
1423949
20.

Methadone-associated Q-T interval prolongation and torsades de pointes.

Stringer J, Welsh C, Tommasello A.

Am J Health Syst Pharm. 2009 May 1;66(9):825-33. doi: 10.2146/ajhp070392. Review. Erratum in: Am J Health Syst Pharm. 2010 Jan 15;67(2):94.

PMID:
19386945

Supplemental Content

Support Center